Barinthus Biotherapeutics PLC
BRNS0.739USD
+0.008+1.04%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
30.17MMarket Cap
LossP/E TTM
More Details of Barinthus Biotherapeutics PLC Company
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Barinthus Biotherapeutics PLC Info
Ticker SymbolBRNS
Company nameBarinthus Biotherapeutics PLC
IPO dateApr 30, 2021
CEOEnright (William J)
Number of employees105
Security typeDepository Receipt
Fiscal year-endApr 30
AddressUnit 6-10, Zeus Building, Rutherford Avenue
CityDIDCOT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeOX11 0DF
Phone441865818808
Websitehttps://www.barinthusbio.com/
Ticker SymbolBRNS
IPO dateApr 30, 2021
CEOEnright (William J)
Company Executives of Barinthus Biotherapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Oxford Science Enterprises PLC
21.55%
M&G Investment Management Ltd.
12.73%
Cawood (Frank Wayne)
8.29%
Alphabet, Inc.
3.71%
HSG Holding Ltd.
3.48%
Other
50.25%
Shareholders
Shareholders
Proportion
Oxford Science Enterprises PLC
21.55%
M&G Investment Management Ltd.
12.73%
Cawood (Frank Wayne)
8.29%
Alphabet, Inc.
3.71%
HSG Holding Ltd.
3.48%
Other
50.25%
Shareholder Types
Shareholders
Proportion
Venture Capital
25.29%
Investment Advisor
17.92%
Individual Investor
13.37%
Endowment Fund
0.30%
Investment Advisor/Hedge Fund
0.29%
Hedge Fund
0.16%
Research Firm
0.05%
Other
42.62%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
17.97M
45.74%
--
2025Q3
32
17.97M
45.74%
-38.01K
2025Q2
30
18.01M
46.38%
+65.89K
2025Q1
30
18.02M
46.62%
-782.82K
2024Q4
29
18.00M
46.88%
-589.55K
2024Q3
29
18.59M
48.15%
-228.24K
2024Q2
30
18.82M
49.02%
+214.04K
2024Q1
29
18.61M
49.21%
-561.80K
2023Q4
34
18.63M
49.81%
+1.21K
2023Q3
36
18.62M
50.13%
-140.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Oxford Science Enterprises PLC
8.80M
21.55%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.73%
--
--
Jun 30, 2025
Cawood (Frank Wayne)
3.38M
8.29%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.71%
--
--
Jun 30, 2025
HSG Holding Ltd.
1.42M
3.48%
--
--
Jun 30, 2025
Enright (William)
1.24M
3.05%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.57%
--
--
Jun 30, 2025
Lynn (Geoffrey)
638.44K
1.56%
+638.44K
--
Dec 17, 2024
Johns Hopkins University
122.24K
0.3%
--
--
Jun 30, 2025
Robert W. Baird & Co. Inc.
192.46K
0.47%
+100.00K
+108.15%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Barinthus Biotherapeutics PLC?
The top five shareholders of Barinthus Biotherapeutics PLC are:
Oxford Science Enterprises PLC holds 8.80M shares, accounting for 21.55% of the total shares.
M&G Investment Management Ltd. holds 5.20M shares, accounting for 12.73% of the total shares.
Cawood (Frank Wayne) holds 3.38M shares, accounting for 8.29% of the total shares.
Alphabet, Inc. holds 1.51M shares, accounting for 3.71% of the total shares.
HSG Holding Ltd. holds 1.42M shares, accounting for 3.48% of the total shares.
Oxford Science Enterprises PLC holds 8.80M shares, accounting for 21.55% of the total shares.
M&G Investment Management Ltd. holds 5.20M shares, accounting for 12.73% of the total shares.
Cawood (Frank Wayne) holds 3.38M shares, accounting for 8.29% of the total shares.
Alphabet, Inc. holds 1.51M shares, accounting for 3.71% of the total shares.
HSG Holding Ltd. holds 1.42M shares, accounting for 3.48% of the total shares.
What are the top three shareholder types of Barinthus Biotherapeutics PLC?
The top three shareholder types of Barinthus Biotherapeutics PLC are:
Oxford Science Enterprises PLC
M&G Investment Management Ltd.
Cawood (Frank Wayne)
Oxford Science Enterprises PLC
M&G Investment Management Ltd.
Cawood (Frank Wayne)
How many institutions hold shares of Barinthus Biotherapeutics PLC (BRNS)?
As of 2025Q4, 31 institutions hold shares of Barinthus Biotherapeutics PLC, with a combined market value of approximately 17.97M, accounting for 45.74% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Barinthus Biotherapeutics PLC?
In --, the -- business generated the highest revenue for Barinthus Biotherapeutics PLC, amounting to -- and accounting for --% of total revenue.
